Oncology

Companion diagnostics domain falls within the larger field of study called pharmacogenomics, which employs the person’s genomic makeup to predict a drug response or to tailor therapy specifically for that patient. The US FDA depicts companion diagnostics as an in vitro diagnostic device or an imaging tool, which provides information essential for the safe and effective use of a corresponding therapeutic, preventive, or prophylactic product. These unprecedented diagnostic devices are the critical part of currently targeted cancer therapy regimens and impose a very good impact on the lowering of the unnecessary morbidity and providing the better treatment access to the p...